Recursion Pharmaceuticals (RXRX)
(Delayed Data from NSDQ)
$6.12 USD
+0.20 (3.38%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $6.12 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for Recursion Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -328.07 | -239.48 | -186.48 | -87.01 | -61.88 |
Depreciation/Amortization & Depletion | 24.40 | 11.76 | 8.41 | 3.94 | 3.04 |
Net Change from Assets/Liabilities | -50.26 | 105.75 | -0.31 | 30.83 | 0.41 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 66.14 | 38.45 | 19.77 | 6.83 | 1.39 |
Net Cash From Operating Activities | -287.78 | -83.52 | -158.61 | -45.40 | -57.04 |
Property & Equipment | -11.96 | -37.06 | -39.80 | -5.83 | -3.91 |
Acquisition/ Disposition of Subsidiaries | 1.84 | 0.00 | 0.00 | -2.60 | 0.00 |
Investments | 0.48 | 230.61 | -231.95 | 0.60 | 0.00 |
Other Investing Activities | -0.60 | -0.30 | 0.00 | -0.90 | 0.00 |
Net Cash from Investing Activities | -10.23 | 193.25 | -271.74 | -8.74 | -3.91 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 128.09 | 143.71 | 462.90 | 239.81 | 119.98 |
Issuance (Repayment) of Debt | -0.77 | -0.09 | -12.80 | 6.32 | 0.71 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 12.81 | 10.72 | 8.44 | 0.00 | -0.28 |
Net Cash from Financing Activities | 140.13 | 154.35 | 458.54 | 246.14 | 120.41 |
Effect of Exchange Rate Changes | 0.19 | -0.31 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -157.69 | 263.76 | 28.18 | 192.00 | 59.46 |
Cash at Beginning of Period | 559.11 | 295.35 | 267.17 | 75.17 | 15.71 |
Cash at End of Period | 401.43 | 559.11 | 295.35 | 267.17 | 75.17 |
Diluted Net EPS | -1.58 | -1.36 | -1.49 | -3.99 | NA |
Fiscal Year End for Recursion Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -188.91 | -91.37 | -328.07 | -235.07 | -142.05 |
Depreciation/Amortization & Depletion | 16.35 | 7.38 | 24.40 | 16.85 | 9.27 |
Net Change from Assets/Liabilities | -46.72 | -36.45 | -50.26 | -38.99 | -34.53 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 34.76 | 18.15 | 66.14 | 43.51 | 26.52 |
Net Cash From Operating Activities | -184.52 | -102.30 | -287.78 | -213.70 | -140.78 |
Property & Equipment | -7.84 | -6.65 | -11.96 | -9.89 | -9.14 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 1.84 | 1.92 | 1.92 |
Investments | 0.00 | 0.00 | 0.48 | 0.48 | 0.00 |
Other Investing Activities | -3.00 | 0.00 | -0.60 | -0.25 | -0.17 |
Net Cash from Investing Activities | -10.84 | -6.65 | -10.23 | -7.74 | -7.39 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 272.42 | 10.87 | 128.09 | 50.00 | 0.00 |
Issuance (Repayment) of Debt | -0.05 | -0.03 | -0.77 | -0.07 | -0.05 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 4.65 | 3.05 | 12.81 | 9.55 | 5.76 |
Net Cash from Financing Activities | 277.02 | 13.90 | 140.13 | 59.47 | 5.71 |
Effect of Exchange Rate Changes | -0.34 | -0.22 | 0.19 | 0.06 | 0.18 |
Net Change In Cash & Equivalents | 81.33 | -95.28 | -157.69 | -161.91 | -142.29 |
Cash at Beginning of Period | 401.43 | 401.43 | 559.11 | 559.11 | 559.11 |
Cash at End of Period | 482.75 | 306.15 | 401.43 | 397.21 | 416.82 |
Diluted Net EPS | -0.40 | -0.39 | -0.43 | -0.43 | -0.38 |